Galderma to buy Zo Skin from Blackstone for $1.5 bln, Reuters reports
Galderma (SIX:GALD) plans to acquire ZO Skin Health from Blackstone (NYSE:BX) for $1.5 billion, according to Reuters. The deal aims to expand Galderma's U.S. presence in the competitive medical skincare market. Galderma, partly owned by L'Oréal, also owns brands like Cetaphil and Alastin.
How this was made
The 30-second read
Why it matters
The deal expands Galderma's U.S. footprint while providing Blackstone with cash from a non‑core asset.
Market read
A material M&A transaction that could influence both the skincare sector and Blackstone's asset mix.
What to watch
Regulatory approvals for the transaction and integration costs could delay value realization.
Background
The article reports the first public disclosure of Galderma's agreement to acquire ZO Skin Health from Blackstone for $1.5 billion.
Ticker impact
Blackstone Inc (NYSE:BX) is selling its ZO Skin Health unit to Galderma for $1.5 billion.
likely modest pressure as the market prices the asset sale
The deal size is material but does not change Blackstone's core investment strategy.
Market effects
Consolidation in the medical‑grade skincare market may benefit peers with stronger distribution networks.
Strengthens Galderma's U.S. presence, potentially boosting European skincare stocks.
Large‑cap M&A adds to overall deal activity, modestly supporting risk‑on sentiment.
Counterpoint
The sale price may be low if ZO Skin Health's growth prospects are undervalued, suggesting a buying opportunity in BX.
Key entities
- CompanyGalderma
Swiss skincare group acquiring ZO Skin Health.
- CompanyBlackstone Inc
Private‑equity firm selling ZO Skin Health.
